UK Blood Pressure Medication Ramipril Recall Raises Concerns Over Packaging Errors and Pharmacy Costs

A UK-based pharmaceutical manufacturer has recalled a batch of ramipril 2.5mg capsules after packaging errors led higher-strength medication to be mixed into lower-dose containers. The discovery marks the third such recall from Crescent Pharma Limited in as many months, prompting pharmacy leaders to demand financial accountability from drug manufacturers.

The Recall Details

The Medicines and Healthcare products Regulatory Agency (MHRA) confirmed that batch number GR155023 of ramipril 2.5mg capsules is being recalled as a precautionary measure. A healthcare professional identified two blister strips of 10mg capsules inside a sealed carton of the lower-dose medication. Both batches were manufactured at the same facility, with the error occurring during the carton packaging stage.

The primary risk associated with the mix-up is unintentional overdosing. Patients prescribed the 2.5mg dose could accidentally take capsules containing four times the intended strength, potentially causing lightheadedness, fainting, fatigue, or altered kidney function. The MHRA's chief safety officer, Dr Alison Cave, advised affected patients to contact their dispensing pharmacy and seek medical evaluation if they believe they have taken higher-dose capsules.

Pattern of Manufacturing Issues

This recall represents a significant pattern for Crescent Pharma. The company previously recalled ramipril 10mg capsules in April and ramipril 5mg capsules in March—all linked to packaging defects. The repeated nature of these errors has intensified pressure on regulatory and pharmacy bodies to address systemic quality control failures within the manufacturing process.

Pharmacy Sector Demands Accountability

The National Pharmacy Association (NPA) has called for manufacturers to be penalised for recall-related costs. Chair Olivier Picard emphasized that pharmacies bear substantial financial and operational burdens: one pharmacist spent eight hours quarantining stock during a previous ramipril recall. Beyond logistical challenges, recalls undermine patient confidence in their medications and create difficult conversations between healthcare providers and those they serve. The NPA is advocating for manufacturers to pay fines proportional to the disruption their mistakes cause within the pharmacy network.